Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma

NCT00474929 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00474929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00474929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
August 29, 2007
Completion date
August 8, 2019
Enrollment
103 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, multiple myeloma and plasma cell neoplasm